header logo image


Page 1,020«..1020..1,0191,0201,0211,022..1,0301,040..»

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M – FinSMEs (blog)

April 29th, 2017 12:47 pm

FinSMEs (blog)
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M
FinSMEs (blog)
Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

Follow this link:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

Read More...

7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. – The Cerbat Gem

April 29th, 2017 12:47 pm

Markets Daily
7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc.
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo David R. Rahn & Associates Inc. acquired a new position in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) during the first quarter, according to its most recent filing with the Securities and Exchange ...
Oakwood Capital Management LLC CA Sells 200 Shares of iShares ...Markets Daily
Parsec Financial Management Inc. Buys 4115 Shares of iShares NASDAQ Biotechnology Index (IBB)BBNS
iShares NASDAQ Biotechnology Index (IBB) Downgraded to "Hold" at Vetr Inc.Transcript Daily
Sherwood Daily -Sports Perspectives -Chaffey Breeze
all 15 news articles »

Link:
7007 Shares in iShares NASDAQ Biotechnology Index (IBB) Acquired by David R. Rahn & Associates Inc. - The Cerbat Gem

Read More...

Arthritis can strike anyone at anytime, regardless of age, physical condition or ethnic background – BCLocalNews

April 29th, 2017 12:47 pm

Doing more to help those living with arthritis may not be the most top-of-mind in this provincial election, but it should be. Political will is, after all, the only thing that stands in front of the opportunity to demonstrably improve the lives of the approximately 650,000 British Columbians living with chronic arthritic pain. Its a change that every single one of us can commit to making part of our decision about who to vote for on May 9.

For most people, waking up, getting dressed, and going about their daily activities is done without a passing thought or worry. But for the 1 out of every 6 British Columbians currently living with arthritis, the chronic joint pain and stiffness associated with the condition can make even the simplest of tasks, such as brushing teeth or putting on socks, an agonizing experience. Improving the care and treatment landscape for people living with arthritis deserves much greater political attention in the upcoming provincial election.

Arthritis can strike anyone at anytime, regardless of age, physical condition or ethnic background. While many people associate the disease with old age, the fact is that more than half of British Columbians living with arthritis are under the age of 65. Arthritis is everywhere, and its impacts are a lot more serious and costly to our province than many people realize.

As it stands, inadequate supports and access to treatment options for people living with arthritis are hurting the B.C. economy. A lot has been done, but we need to see more. Currently, 1 in 4 British Columbians living with the disease of working age report not being able to work due to their condition. Many still are frequently forced to change jobs or reduce work hours, negatively impacting their careers and their livelihoods. In British Columbia, and across the country, the impact of arthritis on the economy, in terms of health care costs and lost productivity, is enormous: an estimated $33 billion each year.

In B.C., almost half of people living with arthritis report having pain that prevents them from doing everyday activities. Having the disease also translates into a three times greater likelihood of having mental health issues, including anxiety and depression, and an 80 per cent chance of having other chronic health issues, such as obesity and diabetes.

Despite all this, arthritis is a long way down the list of issues that get mentioned by political leaders during this years election campaign trail. While the province is faced with another hot-button issue - the ongoing opioid crisis - political leaders must also give due attention to people living with the disease. As part of that, they must recognize that arthritis patients need better access to effective management strategies for their chronic pain.

This includes improved access to promising new therapies, like biologic drugs. These medications have been instrumental in helping many British Columbians living with rheumatoid arthritis, and should be part of the physicians toolbox. As no single biologic therapy works for all arthritis patients, a range of choice among these therapies is critical.

Special attention must also be given to First Nations people, where the prevalence of arthritis is five times higher, and to people all across British Columbia living in rural and remote communities. Prompt diagnosis and treatment are essential to preventing the permanent joint destruction associated with arthritis; however, many people living outside of urban areas face difficulties receiving timely diagnosis and care. There is an urgent need for improved access to specialist expertise and local supports, including homecare, to improve mobility and decrease pain for these underserved populations.

During this election campaign, when candidates knock on your door put them on the spot when it comes to arthritis. Ask them where they stand and whether, if elected, theyre willing to commit resources and embrace new policies to ease the pain of those living with the pain of this disease. Arthritis may not be the number one issue on the minds of candidates. But for 1 in 6 voters, its the number one issue in their lives.

Christine Basque, Executive Director of the BC Division of The Arthritis Society

Read more:
Arthritis can strike anyone at anytime, regardless of age, physical condition or ethnic background - BCLocalNews

Read More...

Feeling under the weather? Arthritis sufferer explores whether link between aches and weather is valid – Mirror.co.uk

April 29th, 2017 12:47 pm

The link between weather and aches and pains may not be such an old wives tale after all.

Retired college lecturer Nora Boswell, 68, has arthritis and is one of 13,000 people taking part in a research project called Cloudy With A Chance Of Pain.

Run by Manchester University and Arthritis Research UK, it is studying the connection between flare-ups and weather.

Here Nora, tells how technology is helping her manage her arthritis .

My mother had bad arthritis in her knees and ten years ago mine started playing up. When Id go down stairs, Id get a sharp pain in my kneecaps. Then it became more debilitating.

Nora, from Thornton, West Yorks, continued: I often walk into the village but I started struggling downhill. It wasnt a real surprise when an X-ray revealed arthritis .

Doctors say I may have deterioration in my shoulders and spine.

I dont like taking painkillers. Theyre a short-term fix. But regular exercise has helped me so much.

I use a Fitbit activity tracker to walk 250 steps an hour and as many squats as possible. Ive got to keep my muscles going.

Arthritis Research UK has excellent exercise routines to help manage pain.

On their website I found an article asking for volunteers for a citizen science four-year study called Cloudy With A Chance of Pain. The results will be out next spring.

Early data revealed people reported less time in severe pain across three UK cities from February to April but pain increased again in June.

Its long been a bit of an old wives tale that the weather can makes aches and pains worse. My chiropractor said many more clients come in after certain weather conditions in pain but there was no proof.

I thought it was great someone was researching it so signed up and downloaded the app.

Ive been logging my pain scale every day on my smartphone while my phone is automatically collecting hourly local weather data. It asks questions, such as how stiff you feel, and you can move a dial to the appropriate level. Ive noticed pain is worse if its damp. We had a long, damp autumn and I got fed up as I couldnt go out for walks.

Hot weather also has a negative affect on it. My husband John and I went on holiday to France and it was very hot.

After two days, I ached. And when we had a hot spell back in the UK my arthritis flared up. So summer beach holidays are out and we go in autumn.

I cant wait to see the results of the study. Until then Ill continue to exercise. I go for a walk most days or use the cross trainer at home. I also go to a pilates class once a week.

If you have arthritis , its also important to pace yourself. Yes, everything takes longer but youll be in less discomfort.

Some people might be OK waiting for someone to give them a pill but youve got to help yourself too.

Continue reading here:
Feeling under the weather? Arthritis sufferer explores whether link between aches and weather is valid - Mirror.co.uk

Read More...

AJ Foyt undergoes stem cell therapy, toe surgery – USA TODAY

April 29th, 2017 12:46 pm

AVONDALE, Arix. Perhaps A.J. Foyts greatest title isnt as the first four-time Indianapolis 500 winner.

Maybe its survivor.

Foyt, whose list of injuries is almost as long as that of his legendary racing achievements, had right foot toe surgery Wednesday just days after stem cell therapy in Mexico. So the winner of Phoenix Raceways debut event in 1964 wont be at Saturday nights Phoenix Grand Prix.

Pain in a smashed smaller toe remnant of a devastating 1990 crash through a dirt embankment at Wisconsins Road America course when his brakes failed was so severe Foyt considered amputation.

Foyt, 82, admits he probably waited too long to try the stem cell therapy, which isnt approved in the U.S. Doctors removed stomach tissue and he explained it takes something like 10 weeks to grow back to produce the stem cells.

Adult stem cells can grow and become part of a specific tissue. Foyt likely wont feel the effects of injections into his shoulders or ankles, two areas the treatment is targeting to relieve pain and gain strength and functionality,for three months.

A..J. Foyt, who is recovering from surgery and wont be at the Phoenix race this season, congratulates 2016 winner Scott Dixon. (Mark J. Rebilas, USA TODAY Sports)

Typical for Foyt, though, he didnt allow his ailments to keep him from completely revamping his two-car ABC Supply Co.-sponsored team after an unsuccessful 2016.

Out: drivers Takuma Sato (now with Michael Andrettis team) and Jack Hawksworth (not in IndyCar). In: former Andretti driver Carlos Munoz, and Conor Daly, in only his second full-time season. Both are 25. Foyt changed to Chevroletengines, from Honda, and moved Dalys crew to a shop almost in sight of the Indianapolis Motor Speedway, while Munoz team operates from Foyts traditional Houston base.

MORE COVERAGE:

WILL PASSING RETURN AT PHOENIX?

DIXON AMONG FAVORITES IN DESERT

CASTRONEVES SETS RECORD, WINS POLE

Sato won the 2013 Long Beach Grand Prix but Foyt called him a little weak and we were just having too many crashes.

Foyts first instructions to Munoz and Daly?

I told them when we started testing: Were not here to set a record or see how fast we can run. Were here to get the cars to where they drive very comfortable. If you crash right off, well be further behind. I dont want you to extend yourself one bit. I just want you to know that.

Said Daly, who father Derek is a former driver, mother Beth a racing sports marketer and event planner, and stepfather Doug Boles IMS president: Youre really driven to try to win for A.J. You can tell how much he still wants to win. Its a cool, emotional deal.

Knight writes for the Arizona Republic, part of the USA TODAY Network.

See the rest here:
AJ Foyt undergoes stem cell therapy, toe surgery - USA TODAY

Read More...

Muscular Dystrophy case treated with stem cell therapy – India.com

April 29th, 2017 12:46 pm

New Delhi, April 29 (IANS) A 20-year-old man suffering from Facioscapulohumeral Muscular Dystrophy (FSHD) a condition which slowly weakens and degenerates all the muscles of the body leading to disability was treated using stem cell therapy at a city-based hospital here.

Aditya Bhatia was diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD) in 2012. It started after he found it difficult to lift his arms over the head one of the main and strongest symptoms. Consultations with several doctors did not find Bhatia any solution, and his condition grew severe and started affecting other parts of the body such as face.

FSHD usually begins before age 20, with weakness and atrophy of the muscles around the eyes and mouth, shoulders, upper arms and lower legs. Later, weakness can spread to abdominal muscles and sometimes hip muscles.

Experts says that FSHD can be divided into adult-onset and infantile-onset forms.

Bhatias parents had heard about the stem cell treatment which had proved effective in many diseases such as spinal diseases. Accordingly, they consulted doctors on stem cell therapy and decided to give it a try.

All the procedures were followed and he was tested for hyper sensitivity reactions with stem cells, also known as Human Embryonic Stem Cell Therapy.

Doctors said that during the treatment procedure, Bhatia was injected with 0.05 ml stem cells.

The treatment included 3 phases T1, T2, T3 so that the stem cell could grow, regenerate and repair the affected part. Each treatment phase lasted 4-6 weeks and was 5 months apart, wherein he was continuously administered by physicians, said Geeta Shroff, Director and Stem cell specialist city based Nutech Mediworld.

She said that in addition to stem cell therapy, Bhatia also received physiotherapy and occupational therapy.

After the treatment he was able to regain his normal life, said Shroff.

This is published unedited from the IANS feed.

Reliance Jio likely to launch broadband Fibre-to-the-Home (FTTH) broadband service soon

13 drown in a stream in Anantapuramu district of Andhra Pradesh after boat capsizes, 4 missing

Triple Talaq issue should not be seen from political prism: PM Modi

jkbose.co.in JKBOSE Higher Secondary Class 12 Part II Annual Exam 2017 Result Soon, check updates here

Nalanda Univ to collaborate with Japan's Kanazawa Univ

See the rest here:
Muscular Dystrophy case treated with stem cell therapy - India.com

Read More...

Cyclist turns a death sentence into a race against diabetes – CNN

April 28th, 2017 3:44 pm

"My mom took me to one doctor who said, 'Your kid has got the flu. Come back in one week,'" he said.

"They said, 'Ma'am, we've got good news, and we've got bad news. The good news is your son's gonna live for now. The bad news is, he's got diabetes. He's got to take shots of insulin, and most likely he'll be dead by 25. If not, he'll either be blind or have renal failure,'" he said.

As he grew up in Tallahassee, Florida, Southerland was determined not to let this death sentence stop him. At 6, he was already managing his Type 1 diabetes on his own.

"For me, it was all I ever knew. I knew I had to breathe, I knew I had to eat and I knew I had to check my blood sugar and give myself insulin shots."

His parents stored only healthy food in the house to keep him from making bad choices. But at 12, Southerland disobeyed the rules and ate a candy bar. That decision would change his life.

"I figured OK, I don't want to wait two hours for my insulin to kick in. I do want to eat these candy bars. How can I do it?" he recalled.

So he hopped on his bike and rode through the neighborhood until his legs got tired.

"That was my journey to start riding," he said. "The bike for me was freedom."

The more he exercised, the less insulin he needed, and the easier it was to manage the disease.

"The bike gave me the discipline and motivation I needed to control my diabetes," he added.

The first sporting goal of the organization was to have a team of athletes compete in the Race Across America, a 3,000-mile bike trek through 12 states.

"We lost the race by three minutes," Southerland said. "So we came back the next year a little smarter in how we manage diabetes, a little more experienced in the race, and we set a world record of 5 days, 15 hours and 43 minutes."

To ensure safety, the organization provides a medical team to support riders during a race. Cyclists undergo a stringent testing regime in the three hours leading up to a race. They also use continuous glucose monitoring, which will sound an alarm if their levels get too high or too low.

In 2008, Southerland created a professional team of diabetic cyclists.

"I was supposed to be dead when we started Team Type 1 as a professional cycling team," he said.

But he was far from it. Southerland competed as a professional cyclist for two years until some injuries took him out of the sport.

Now 35, Southerland's goal is to field the first all-diabetic team in the Tour de France by 2021.

"I believe sport can be the unifying point for people with diabetes," he said.

Southerland's other passion is helping diabetic kids in Rwanda get much-needed medical supplies.

"I nearly put our company out of business in 2010 ... because I bought 400 blood glucose monitors, and I took about 40,000 test strips in bike boxes to the Tour of Rwanda," he said.

"We gave them out to the kids there. Their parents were all in tears because their kids have this tool, which is gonna help them live," he added. "It ripped my heart out."

Every year since then, the organization has continued to send supplies to Rwanda.

"I want every kid with diabetes to know that they are the hero. Every person with diabetes to know that their dreams can come true."

Read this article:
Cyclist turns a death sentence into a race against diabetes - CNN

Read More...

Type 2 Diabetes May Be Bad for Brain Health – WebMD

April 28th, 2017 3:44 pm

By Serena Gordon

HealthDay Reporter

THURSDAY, April 27, 2017 (HealthDay News) -- Previous research has linked type 2 diabetes and memory loss. Now, new research may be closing in on some of the reasons why.

The study found that people with type 2 diabetes -- particularly those who are overweight or obese -- have thinner gray matter in several areas of the brain.

These brain regions are related to memory, executive function, movement generation and visual information processing, said the study's senior author, Dr. In Kyoon Lyoo. He's director of the Ewha University Brain Institute in Seoul, South Korea.

"Obesity leads to increased risk of type 2 diabetes, metabolic dysfunction and is also associated with brain alterations independently," Lyoo said. "We aimed to investigate whether overweight/obesity influenced brain structure and cognitive function in individuals with early stage of type 2 diabetes."

The study included: 50 overweight or obese people with type 2 diabetes; 50 normal-weight people with type 2 diabetes, and 50 normal-weight people without diabetes.

The Korean study volunteers were between 30 and 60 years old. Those with diabetes had it for five years or less, and they were attempting lifestyle modifications and/or taking oral medication to lower blood sugar levels. No one was taking insulin.

The normal-weight group with type 2 diabetes had slightly better blood sugar control -- a hemoglobin A1C level of 7 percent. The overweight folks with type 2 diabetes had hemoglobin A1C levels of 7.3 percent.

Hemoglobin A1C is a two- to three- month estimate of average blood sugar levels. The American Diabetes Association generally recommends an A1C of 7 percent or less.

All study participants underwent MRI brain scans and tests to measure memory and thinking skills.

"Cortical thickness was decreased in several regions of the diabetic brains. Further thinning of the temporal lobes found in overweight/obese individuals with type 2 diabetes suggests that these regions are specifically vulnerable to combined effects of obesity and type 2 diabetes," Lyoo said.

He said this study alone cannot tease out whether the effect is from excess weight or diabetes or both. But the study did find that the longer someone had diabetes, the more likely they were to have brain changes.

Lyoo said factors such as insulin resistance, inflammation and poor blood sugar management might bring about the changes.

Memory and thinking skills were decreased in people with diabetes -- regardless of weight -- compared to the normal-weight people without type 2 diabetes, the study found.

Because the study only included an Asian population, Lyoo said it isn't clear if these effects would apply to other populations, such as Americans. He also said it isn't known if these effects occur in people with type 1 diabetes, the less common form of diabetes.

Dr. Sami Saba is an attending physician in neuromuscular medicine and electromyography at Lenox Hill Hospital in New York City.

"The regions most affected were the temporal lobes, which are also most prominently affected in people with Alzheimer's," he said of the research.

"While this was not proven on this study, it does suggest that those with diabetes who are also overweight are at higher risk for developing Alzheimer's-type cognitive impairment than those with diabetes who are not overweight," Saba said.

But, he also noted that a major limitation of this study was the lack of overweight/obese people without diabetes to serve as a comparison group.

The take-home message, said Saba, is that weight control is an "important factor in preserving brain health in these patients." He said it's one more reason to work to prevent weight gain.

Lyoo said good blood-sugar management would probably help slow down or prevent these diabetes- or obesity-related brain changes.

Dr. William Cefalu is the chief scientific, medical and mission officer for the American Diabetes Association.

"The presence of overweight and obesity has been shown in other studies to be associated with early structural changes in the brain, and may contribute to cognitive issues," he said.

But, he said that diabetes may also play a role. Both Lyoo and Cefalu said that more research is needed to figure out which factor is at the root of these changes.

The study was released April 27 in the journal Diabetologia.

WebMD News from HealthDay

SOURCES: In Kyoon Lyoo, M.D., Ph.D., director, Ewha University Brain Institute, Seoul, South Korea; Sami Saba, M.D., attending physician in neuromuscular medicine and electromyography, department of neurology, Lenox Hill Hospital, New York City; William Cefalu, M.D., chief scientific, medical and mission officer, American Diabetes Association; April 27, 2017, Diabetologia

View original post here:
Type 2 Diabetes May Be Bad for Brain Health - WebMD

Read More...

With a motor and a mentor, elite basketball recruit Cate Reese moves forward with diabetes – ESPN

April 28th, 2017 3:44 pm

By Walter Villa | Apr 27, 2017 Sepcial to espnW

Courtesy the Reese family

Senior night was emotional for Cate, left, and Ali Reese, not to mention all the friends and family in the stands.

When Cate Reese was 2 years old, she scampered on tiny legs from the front door of the family townhouse to the back. Then she did it again. And again. And again.

Fifteen years later, the 6-foot-3 junior forward for Cypress Woods (Cypress, Texas) and the No. 14 prospect in the espnW HoopGurlz Super 60 for 2018 class is still in constant motion. Reese beats opponents from rim to rim. She fidgets in the huddle. She chews gum incessantly. Movement every second.

"It's crazy how much gum I buy," said her mom, Cheryl. "I buy 10 packs at a time, and she blows through it."

Reese has been a starter since her freshman year, when she helped lead Cypress Woods to its only state title. She averaged 22.3 points and 13.2 rebounds this past season, making first-team all-state.

Not even the life-altering news she got a year ago has been able to stop her.

On April 4, 2016, Reese was told she had Type 1 diabetes, a diagnosis that stunned her even though her older sister, Ali, has dealt with the same disease for the past eight years. Cate had hoped to avoid that fate.

"Initially, it was devastating for Cate," Cypress Woods coach Virginia Flores said. "I pulled her into my office and asked her what was getting to her the most about her situation. ... To her, everything and everyone is beatable. But diabetes is not something you defeat. It's something you manage. So when she said, 'This is forever,' my heart just broke for her in that moment."

She's learned a lot about her disease and herself since that day.

"It's made me see life through a different perspective," she said. "You only get one life to live. I'm grateful I can still play. I'm still here."

Courtesy the Reese family

Basketball programs across the country are trying to land Cate Reese, right, for college. It could be that she'll stick by her sister's side.

Reese was a premature baby, and she was kept in the hospital's neonatal intensive care unit for three weeks because her lungs were not developed enough at birth.

Cheryl said she never saw her daughter cry or even move.

She was brought home on a memorable Thanksgiving eve. Soon after, came the pulling, pushing, crying. And crawling. Before long, her favorite saying: "Are you going to eat that?"

She was precocious, too. At age 4, she told her parents she was no longer Catherine or Catie. She was Cate. "I guess I was pretty sassy," Reese said.

She started playing basketball at age 7, and she has grown in her game and in her stature. She is six inches taller than her sister and mother and maybe just a hair taller than Bill, her father.

Bill, by the way, wasn't much of an athlete and didn't expect Cate to be nearly this good.

"She was always tall, but she was gawky," he said. "I always used to tell her, 'You are going to be this tall [player] at the end of the bench.'"

Courtesy the Reese family

Ali Reese, left, recognized the danger signs in Cate and has helped guide her through the uncertain times caused by diabetes.

Bill Reese was spectacularly wrong.

By Cate's freshman year, she averaged 12.2 points and 8.3 rebounds on that championship team that featured five other Division I recruits. She averaged 20.8 points and 12.8 rebounds as a sophomore, the same year she joined the Texas Elite AAU team.

It was there that she impressed coach Joey Simmons.

"She's a bulldog," Simmons said. "She plays as hard as anybody I've coached. If the ball is loose, she is diving at it, jumping for it, pushing, shoving -- anything it takes. She never stops the whole game. She's a special player when it comes to being relentless."

You only get one life to live. I'm grateful I can still play. I'm still here.

Cate Reese

Simmons said Arizona, South Carolina and Texas A&M have been pushing hard to sign Reese. But Reese said she has yet to decide on favorites.

She is grateful, however, that her parents have been involved, accompanying her on unofficial visits to numerous colleges. Reese said she prefers a warm-weather school but is open to all possibilities. So far, she has visited Colorado, Washington, SMU, Texas Tech, Baylor, Texas Christian, Oklahoma State, Rice, Arizona, South Carolina, Texas A&M and George Washington, and she has scholarship offers from all those schools.

"She's a phenomenal athlete," Ali said of her sister, who is a senior on the Cypress Woods team. "She has a huge passion for the game that I don't see in other people."

Indeed, Cate's competitiveness is legendary among those who know her well.

"When I lose," Cate said, "it's not a fun car ride home."

Ali wants to study nursing but will not continue with basketball in college. Cate, who has more than 1,000 career rebounds and is less than 200 away from 2,000 points, wants to pick a school by September.

Both girls want to attend the same college, if possible. So wherever Ali goes ... Cate may follow.

Courtesy the Reese family

The one thing Cate Reese didn't want to share with her sister was diabetes.

The sisters have always been close, but the events of the last year have brought them even closer.

It was Ali who saw her sister overly thirsty last year and immediately tested Cate's blood sugar, forcing an urgent trip to the hospital and avoiding a situation that could have become dire if left unattended.

And it's Ali who has been there to answer Cate's questions, let her know what to expect and guide her in her new reality.

On the court, though, the sisters yelled at each other so much that Flores told them they would not play together if they couldn't find a way to get along.

"I get very passionate, and I yell at people," Cate said. "But I don't mean it like that -- I just get excited."

Cate is disappointed that Ali has chosen not to pursue college basketball.

"She has the skills to play at the next level," Cate said. "I love basketball so much that it's hard to believe when others don't love it as much as I do."

A couple of months ago, on senior night, tears flowed on the court as fans, friends and family watched the ceremony. And the sisters.

"Along the way," Cate said, "I've met a lot of teammates who have become like my sisters. But it's been great the past two years of high school and the past four years in AAU to play with my actual sister. It's hard to put into words how much she means to me. She's my biggest supporter and my best friend. I don't know what I would do without her."

Go here to see the original:
With a motor and a mentor, elite basketball recruit Cate Reese moves forward with diabetes - ESPN

Read More...

Diabetes Fundraiser Adds Extreme Ninja Course – CBS Local

April 28th, 2017 3:44 pm

By Libby Smith

DENVER (CBS4) The American Diabetes Association kicked off fundraising for its Tour de Cure event this week.

Tour de Cure features a family-friendly walk, a 5-K run, four bike tour routes, and, new this year, an obstacle course. The Extreme Ninja Course will have up to nine obstacles that participants will need to get through.

LINK: Tour de Cure 2017

We want to be dynamic in the field of events, said Brandi Miller, the coordinator for Tour de Cure.

CBS4s Ashton Altieri tries out the Xtreme Obstacle Course. (credit CBS)

Xtreme Obstacle Course is the company that will be providing the course for Tour de Cure, and they had a smaller version set up at Blue Moon RiNo Brewery for the kickoff event Thursday. CBS4s Ashton Altieri tried out the course. At Tour de Cure, contestants can compete individually or in teams.

LINK: Xtreme Obstacle Course

Between the new ninja-style course, the walk, the run and the bike tours, the ADA hopes to raise $1,400,000.

(credit CBS)

The money thats raised at Tour goes to our advocacy. It goes toward research. It goes towards our programs that we have here in Colorado. We have camps for kids living with diabetes, Miller explained.

(credit CBS)

Lockheed Martin has been a part of Tour de Cure for at least the 10 years Ive been doing it, said John Donovan, leader for the local Lockheed Martin team.

So John, your team was the top fundraising team nationally, tell me about your fundraising strategy? Altieri asked Donovan.

The strategy is getting a large membership and encouraging those people to go out and just get $5 or $10 from somebody. It can be coworkers, it could be family, it could be neighbors, Donovan replied.

Tour de Cure is Saturday, Sept. 92017. Now is the time to sign-up for an event, form a team, begin your training, and start fundraising.

Libby Smith is a Special Projects Producer at CBS4. If you have a story youd like to tell CBS4 about, call 303-863-TIPS (8477) or visit the News Tips section.

Read the original post:
Diabetes Fundraiser Adds Extreme Ninja Course - CBS Local

Read More...

Calling All Heart Docs – Your Diabetes Drugs Need You – Seeking Alpha

April 28th, 2017 3:44 pm

Astrazeneca (NYSE:AZN) followed Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) this morning by delivering a disappointing performance from its SGLT-2 inhibitor Farxiga. The drug belongs to a class that is widely projected to become the fastest growing among diabetes medicines (see tables below).

As such, weak first-quarter sales from the main players is worrying, and the blame is being laid at the feet of US pricing pressures. Diabetes is an area where payers have successfully flexed their muscles. However, it seems that another factor is playing a role: the message that this class can reduce a patient's risks from heart disease is taking time to have an impact.

Astrazeneca said growing intra-class competition and the impact of affordability programmes and managed-care access subdued Farxiga growth in the US, where sales inched only 2% higher, to $96m, in the first quarter.

J&J painted an even worse picture with Invokana - lower prices caused US sales of the medicine to fall 13% on the same quarter of last year. The company also blamed increasing discounts for managed care and a higher composition of Medicaid sales, where prices are typically lower.

The Lilly result was probably the most surprising given that the company has been heavily marketing Jardiance's success in its cardiovascular outcome study since January. New patient starts have surged 75% since the company was allowed to begin marketing on evidence that the drug can reduce the risks of death and complications from heart disease, the company said this week. However revenues still came in lower than the sell-side was expecting.

Lilly and partner Boehringer Ingelheim are the only companies allowed to actively market a cardiac benefit for their SGLT2, although big studies are due to report on Invokana and Farxiga in the next couple of years. These are widely expected to confirm a class effect, helping to drive use of all of these medicines (ACC - Jardiance heart benefit looks like a class effect, March 20, 2017).

However, the finding represents a big philosophical shift for this area of medicine, which is more used to dealing with the discovery of safety signals.

"We have to remember we are talking about changing very well entrenched treatment practises and physicians do take some time to get comfortable with new drugs and new classes," said Mark Mallon, head of Astrazeneca's global product strategy and medical affairs, in a media call this morning. "They need to see the data and the data is absolutely coming. But it's going to take time to build that up."

Assuming the class effect is confirmed, having three companies actively promoting a cardiac benefit will surely help drive uptake. However another issue is bringing cardiologists on board - endocrinologists and primary care doctors are currently the main prescribers of these drugs - an issue that Lilly executives have said they are closely monitoring.

"Cardiologists, in the case of Jardiance, are a significant source of authority. And while we have seen an increase, the base of prescribing is extremely, extremely small," Enrique Conterno, head of Lilly's diabetes business, told analysts on a call last week.

Merging therapy areas

The discovery of cardioprotective benefits for the SGLT2s and to a lesser extent the GLP-1 agonists points to a merging of therapy areas that looks set to become only more apparent in the coming years.

Novo Nordisk (NYSE:NVO) has already won approval for Victoza as an obesity therapy. Astrazeneca this year started two outcome trials with Farxiga in heart failure and chronic kidney disease, which will recruit both diabetic and non-diabetic patients. And its blood thinner Brilinta is being trialed in diabetic patients in the huge Themis study, to see if it can reduce the risk of heart attack and stroke.

The UK pharma giant has even merged its cardiovascular and diabetes drugs into a single reporting unit, which chief executive Pascal Soriot put down to more and more overlap.

"We believe there are substantial synergies across those therapy areas - operationally in the field but also from a medical view point," he told journalists earlier today.

A cynic might also see the move as a convenient way to de-emphasise Brilinta, sales of which have long disappointed.

However it is readily apparent that the SGLT2s have the potential to steer the treatment of diabetics closer to the cardiovascular world than ever before. The extent to which these drugs will be embraced by cardiologists is hard to foresee until more trials report, but could have a huge impact on the commercial potential of the class.

More:
Calling All Heart Docs - Your Diabetes Drugs Need You - Seeking Alpha

Read More...

Diabetes app forecasts blood sugar levels: First-of-its-kind … – Science Daily

April 28th, 2017 3:44 pm

Healthline
Diabetes app forecasts blood sugar levels: First-of-its-kind ...
Science Daily
Glucoracle is a new app for people with type 2 diabetes that uses a personalized algorithm to predict the impact of particular foods on blood sugar levels.
Diabetes App Designed to Predict Blood Sugar Levels After Each MealHealthline

all 3 news articles »

See original here:
Diabetes app forecasts blood sugar levels: First-of-its-kind ... - Science Daily

Read More...

Stem cell lines grown in lab dish may acquire mutations – Harvard Gazette

April 28th, 2017 3:42 pm

Photo by Hannah Robbins/HSCI

In a cross-school collaboration, Harvard researchers Steve McCarroll (left) and Kevin Eggan couple stem cell science with genetics and genomicsto advance the understanding of human brain illnesses. Their latest project identifiedmutations that stem cell lines acquire in culture.

Regenerative medicine using human pluripotent stem cells to grow transplantable tissue outside the body carries the promise to treat a range of intractable disorders, such as diabetes and Parkinsons disease.

However, a research team from the Harvard Stem Cell Institute (HSCI), Harvard Medical School (HMS), and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard has found that as stem cell lines grow in a lab dish, they often acquire mutations in the TP53 (p53) gene, an important tumor suppressor responsible for controlling cell growth and division.

Their research suggests that genetic sequencing technologies should be used to screen for mutated cells in stem cell cultures, so that cultures with mutated cells can be excluded from scientific experiments and clinical therapies. If such methods are not employed it could lead to an elevated cancer risk in those receiving transplants.

The paper, published online today in the journal Nature, comes at just the right time, the researchers said, as experimental treatments using human pluripotent stem cells are ramping up across the country.

Our results underscore the need for the field of regenerative medicine to proceed with care, said the studys co-corresponding author Kevin Eggan, an HSCI principal faculty member and the director of stem cell biology for the Stanley Center. Eggans lab in Harvard Universitys Department of Stem Cell and Regenerative Biology uses human stem cells to study the mechanisms of brain disorders, including amyotrophic lateral sclerosis, intellectual disability, and schizophrenia.

The research, the team said, should not discourage the pursuit of experimental treatments but instead be heeded as a call to screen rigorously all cell lines for mutations at various stages of development as well as immediately before transplantation.

Our findings indicate that an additional series of quality control checks should be implemented during the production of stem cells and their downstream use in developing therapies, Eggan said. Fortunately, these genetic checks can be readily performed with precise, sensitive, and increasingly inexpensive sequencing methods.

With human stem cells, researchers can re-create human tissue in the lab. This enables them to study the mechanisms by which certain genes can predispose an individual to a particular disease. Eggan has been working with Steve McCarroll, associate professor of genetics at Harvard Medical School and director of genetics at the Stanley Center, to study how genes shape the biology of neurons, which can be derived from these stem cells.

McCarrolls lab recently discovered a common, precancerous condition in which a blood stem cell in the body acquires a pro-growth mutation and then outcompetes a persons normal stem cells, becoming the dominant generator of his or her blood cells. People in whom this condition has appeared are 12 times likelier to develop blood cancer later in life. The studys lead authors, Florian Merkle and Sulagna Ghosh, collaborated with Eggan and McCarroll to test whether laboratory-grown stem cells might be vulnerable to an analogous process.

Cells in the lab, like cells in the body, acquire mutations all the time, said McCarroll, co-corresponding author. Mutations in most genes have little impact on the larger tissue or cell line. But cells with a pro-growth mutation can outcompete other cells, become very numerous, and take over a tissue. We found that this process of clonal selection the basis of cancer formation in the body is also routinely happening in laboratories.

To find acquired mutations, the researchers performed genetic analyses on 140 stem cell lines 26 of which were developed for therapeutic purposes using Good Manufacturing Practices, a quality control standard set by regulatory agencies in multiple countries. The remaining 114 were listed on the National Institutes of Health registry of human pluripotent stem cells.

While we expected to find some mutations in stem cell lines, we were surprised to find that about 5 percent of the stem cell lines we analyzed had acquired mutations in a tumor-suppressing gene called p53, said Merkle.

Nicknamed the guardian of the genome, p53 controls cell growth and cell death. People who inherit p53 mutations develop a rare disorder called Li-Fraumeni Syndrome, which confers a near 100 percent risk of developing cancer in a wide range of tissue types.

The specific mutations that the researchers observed are dominant-negative mutations, meaning that when they are present on even one copy of p53, they are able to compromise the function of the normal protein, whose components are made from both gene copies. The exact same dominant-negative mutations are among the most commonly observed mutations in human cancers.

These precise mutations are very familiar to cancer scientists. They are among the worst p53 mutations to have, said Ghosh, a co-lead author of the study.

The researchers performed a sophisticated set of DNA analyses to rule out the possibility that these mutations had been inherited rather than acquired as the cells grew in the lab. In subsequent experiments, the Harvard scientists found that p53 mutant cells outperformed and outcompeted non-mutant cells in the lab dish. In other words, a culture with a million healthy cells and one p53 mutant cell, said Eggan, could quickly become a culture of only mutant cells.

The spectrum of tissues at risk for transformation when harboring a p53 mutation includes many of those that we would like to target for repair with regenerative medicine using human pluripotent stem cells, said Eggan. Those organs include the pancreas, brain, blood, bone, skin, liver, and lungs.

However, Eggan and McCarroll emphasized that now that this phenomenon has been found, inexpensive gene-sequencing tests will allow researchers to identify and remove from the production line cell cultures with worrisome mutations that might prove dangerous after transplantation.

The researchers point out in their paper that screening approaches to identify these p53 mutations and others that confer cancer risk already exist and are used in cancer diagnostics. In fact, in an ongoing clinical trial that is transplanting cells derived from induced pluripotent stem cells, gene sequencing is used to ensure the transplanted cell products are free of dangerous mutations.

This work was supported by the Harvard Stem Cell Institute, the Stanley Center for Psychiatric Research, the Rosetrees Trust, the Azrieli Foundation, Howard Hughes Medical Institute, the Wellcome Trust, the Medical Research Council, the Academy of Medical Sciences, and by grants from the NIH.

By Al Powell, Harvard Staff Writer | April 26, 2017

Original post:
Stem cell lines grown in lab dish may acquire mutations - Harvard Gazette

Read More...

Artificial intelligence shows potential to fight blindness – Science Daily

April 28th, 2017 3:42 pm
Artificial intelligence shows potential to fight blindness
Science Daily
Diabetic retinopathy (DR) is a condition that damages the blood vessels at the back of the eye, potentially causing blindness. "What we showed is that an artificial intelligence-based grading algorithm can be used to identify, with high reliability ...

and more »

Original post:
Artificial intelligence shows potential to fight blindness - Science Daily

Read More...

‘State of the Swamp’ Spotlights Trump Team’s Ethical Blindness – Common Dreams

April 28th, 2017 3:42 pm

Common Dreams
'State of the Swamp' Spotlights Trump Team's Ethical Blindness
Common Dreams
'This president's first hundred days have seen no progress in 'draining the swamp;' instead, they have been the most corrupt in our national history.' (Image: Common Cause). President Trump marks his 100th day in office on Saturday, a milestone he ...

Read the original here:
'State of the Swamp' Spotlights Trump Team's Ethical Blindness - Common Dreams

Read More...

New glaucoma test could save millions from blindness – NHS Choices

April 28th, 2017 3:42 pm

Thursday April 27 2017

Glaucoma develops slowly over many years

"It might be possible to treat the main cause of permanent blindness before people notice any loss of vision," BBC News report.

A proof of concept study of early testing for glaucoma the most common cause of sight loss had promising results.

In glaucoma, the light-sensitive cells of the retinal nerve die, usually because of increased pressure in the eye. The damage to the nerve, which is irreversible, causes progressive loss of vision. Because people with glaucoma often don't have symptoms in the early stages of the disease, a lot of damage may be done before it is picked up. Diagnosing glaucoma early would allow earlier treatment to relieve pressure in the eye, and may prevent sight loss.

The new technique involves injecting people with a fluorescent dye (thankfully into the bloodstream, not the eye), and taking images of the eye. Dying retinal nerve cells show up as white spots on the image.

Researchers compared images from eight people with early glaucoma and eight healthy people, and showed that white spots were more than twice as common in people with glaucoma. They also seemed more common in people whose glaucoma got worse quickly over time.

However, the technique needs to be tested in large-scale studies to confirm the result as well as find out more about any safety issues.

The study reinforces the importance of having regular eye tests as these can oftenpick up glaucomabefore it becomes a significant problem. You should have an eye test at least every two years.

The study was carried out by researchers from Western Eye Hospital, Imperial College and University College London and was funded by the Wellcome Trust. The study was published in thepeer-reviewed journal Brain on anopen-access basis so it is free to read online.

BBC News, ITV News and The Daily Telegraph all covered the story. Their reports were mostly accurate and balanced, although none made clear the amount of research that still needs to be done before the new test can be put into use.

This was an open label,phase one clinical trial designed to establish proof of concept. Trials of medicines and tests go through three phases to ensure they are safe and effective.

The study was the first done in humans, so researchers wanted to know if it worked, if it caused any adverse effects, and what effect different doses of the dye had. They will now need to dophase 2and phase 3 trialson much bigger groups of patients to confirm their initial results.

Researchers recruited eight healthy adults without eye disease and eight adults being treated for early glaucoma at the hospital, with no other eye disease. People had an injection of the fluorescent dye (one of four different doses) then had their eye scanned by an infrared laser ophthalmoscope. The researchers assessed the images and compared those from healthy people and people with glaucoma.

Everyone was given a full eye examination when they were recruited, on the day of the test, and 30 days later. They were monitored for adverse events from the injection for six hours, with a phone call 24 hours later.

Researchers also looked to see what happened to the people with glaucoma during their future clinical follow-up visits, for up to 16 months. They then looked to see if the test results predicted how their glaucoma progressed.

Participants with glaucoma had on average more than twice as many white spots showing dying nerve cells as people with healthy eyes (2.37-fold increase, 95%confidence interval 1.4 to 4.03).

People with glaucoma whose disease got worse over the following months also had more white spots than those whose disease stayed the same. Among people without eye disease, older people had more white spots.

Glaucoma is more common among people aged over 75.

No-one had major side effects linked to the injection (one person found it painful and one person had a bruise afterwards).

The researchers stress their results need to be confirmed by bigger trials, saying: "Like any new technology," it will "need robust testing if it is to be successfully validated."

However, they say, it might be possible to use the test "as a method of detection and monitoring of patients" with glaucoma. They say they have shown that the technique may be useful for identifying nerve degeneration.

They further theorise that it might one day be used for other diseases, including the eye disease macular degeneration, optic neuritis (inflammation of the optic nerve) and "Alzheimers-related disease."

Glaucoma is responsible for about 10 in 100 people registered blind in the UK. About 2 in 100 people over 40 in the UK have glaucoma, and around 10 in 100 of those aged over 75. Because there is no cure, but early treatment can often help slow or prevent damage, early diagnosis is important.

Regular eye tests may pick up glaucoma, but often there's no sign of the disease until people have already begun to lose vision. That's why this test is interesting. If it can be shown to work well and safely, it could be a quick and efficient way to diagnose glaucoma before people have started to lose their sight. However, there's more work to do before we get to that stage.

The initial trial results in 16 people need to be repeated among bigger groups, to be sure the results hold true. The researchers need to establish the best dose of the fluorescent dye. Importantly, they need to establish what number of white dots is normal, and what number suggests early glaucoma. This research only shows that people with glaucoma had more white dots, not what would be a good cut-off point for early diagnosis.

Everyone should have a routine eye test at least every two years. This may include a test for high pressure in the eye, as well as a sight test.

If a close relative has glaucoma, mention it to the optician to be sure they carry out appropriate checks. Some types of glaucoma can run in families, so if you do have a family history, more frequent tests may be recommended.

Read more from the original source:
New glaucoma test could save millions from blindness - NHS Choices

Read More...

A college’s willful blindness to a sexual assault scandal – The … – Washington Post

April 28th, 2017 3:42 pm

THEY JUST didnt listen. So said one gymnast allegedly molested by Larry Nassar, a former USA Gymnastics doctor at the center of a sexual abuse scandal. Dr. Nassar also worked at Michigan State University where multiple female athletes complained to officials about his so-called treatment, only to have the school shamelessly and shamefully ignore them.

USA Gymnastics has borne the brunt of the blame for Dr. Nassars alleged exploits. But, as reporting by The Posts Will Hobson and the Lansing State Journal reveals, Michigan State shares responsibility for letting an alleged abuser reportedly carry on a decades-long criminal career. When athletes there told coaches and administrators that Dr. Nassar had massaged their buttocks and inserted his fingers, without gloves, into their vaginas, the officials told them they were misinterpreting the work of a medical superstar. A university Title IX investigation in 2014 cleared Dr. Nassar of wrongdoing.

Dr. Nassar worked with aspiring Olympians across the country, and a nationwide network of coaches and officials apparently let their athletes down again and again. But that bigger story should not obscure the appalling series of events that played out on Michigan States campus, for which the school has no excuse. Authorities say Dr. Nassar was brazen in his abuse, to the point where, as FBI agents discovered during their investigation, he allegedly recorded video of himself groping underage girls in a pool.

Michigan State is undergoing internal reviews to figure out what went so terribly wrong on its watch. Thats important, but equally important are structural reforms at Michigan State and colleges across the country to hold abusers accountable and prevent abuse from occurring in the first place. Michigan States shortcomings underscore the importance of the Education Departments recent efforts to more carefully enforce Title IX, which governs how schools address sexual violence. Troublingly, Education Secretary Betsy DeVos would not commit to continuing those efforts in her confirmation hearing.

I have been told it is virtually impossible to stop a determined sexual predator and pedophile, that they will go to incomprehensible lengths to keep what they do in the shadows, Michigan State President Lou Anna Simon said at a meeting of trustees this month. But Dr. Nassar was not in the shadows. He and his behavior were on full display, for years, waiting for administrators to take action. They chose not to listen, and they chose not to see.

Go here to see the original:
A college's willful blindness to a sexual assault scandal - The ... - Washington Post

Read More...

Protecting eyes from ultraviolet rays can prevent blindness – Portsmouth Daily Times

April 28th, 2017 3:42 pm

Many people know about the damage that ultraviolet (UV) rays can have on the skin, from sunburns to skin cancers. But many may not know about the damage it may cause to the eyes. That is why the Ohio Affiliate of Prevent Blindness has declared May as UV (ultraviolet) Awareness Month. The goal is to help educate the public on the dangers of UV and steps to take to protect vision today and in the future.

UV damage to the eyes can be immediate, including a condition called ultraviolet keratitis. According to the Cleveland Clinic, this occurs from exposure to ultraviolet rays that can temporarily damage the cornea (the clear portion of the eye in front of the pupil) and the conjunctiva, a layer of cells covering the inside of the eyelid and the whites of the eye. Symptoms, such as eye pain, tears, blurred vision, light sensitivity and seeing halos, may last from 6 to 24 hours, but they usually disappear within 48 hours.

However, some UV damage may be cumulative, leading to cataract or macular degeneration later in life. People who work or play in the sun for long periods of time are at the greatest risk. Parents should make sure that children are wearing the proper sun protection at all times when outdoors.

When purchasing sunglasses, Prevent Blindness also recommends buying sunglasses that:

Sunglasses should be worn in conjunction with a brimmed hat. Wrap-around sunglasses are best as they protect not only the eyes but the delicate skin around the eyes as well.

The best way to protect your eyes, and your familys eyes from UV, is to talk with an eyecare professional. By discussing your unique needs, he or she can provide guidance on the best ways to protect your eyes today and help ensure healthy vision for years to come, said Sherry Williams, President &CEO of Prevent Blindness, Ohio Affiliate.

For more information on the dangers of UV exposure and how to choose the best UV protection, please visit the Prevent Blindness dedicated Web page at http://www.preventblindness.org/protect-your-eyes-sun or Prevent Blindness, Ohio Affiliate at call (800) 301-2020.

.

Follow this link:
Protecting eyes from ultraviolet rays can prevent blindness - Portsmouth Daily Times

Read More...

Mexico Eliminates The Infectious Disease That Is The Leading … – Konbini

April 28th, 2017 3:42 pm

Trachoma is the leading infectious cause of blindness worldwide. The disease causes the inner surface of eyelids to become rough, potentially ending up in visual impairment. On average, trachoma affects 1.9 million people around the world. It mainly harms people living in poor areas.

On Monday, the Pan American Health Organization (PAHO) and the World Health Organization (WHO) announced that after more than ten years of effort, Mexico managed to eliminate trachoma.

This was achieved through the Trachoma Prevention and Control program promoted by the Ministryof Health inChiapas, Mexico, since 2004, as well as the "Trachoma Brigades" to promote hygiene and provide information and antibiotics to those affected in vulnerable areas of the state.

Thanks to these efforts, it was possible to reduce the number of cases from 1,794 in 2004 to0 in 2016.

(Source: GIPHY)

With this monumental achievement, Mexico becomes the first country in the Americas and the third in the world (after Oman and Morocco) to receive WHO validation for eliminating trachoma.

Read More ->The World's First Malaria Vaccine Is Here, And Africa Gets It First

Read the original post:
Mexico Eliminates The Infectious Disease That Is The Leading ... - Konbini

Read More...

Bosan for establishing Islamic Biotechnology Centre – Pakistan Observer

April 28th, 2017 3:41 pm

Staff Reporter

Islamabad

Minister for National Food Security and Research Sikandar Hayat Khan Bosan called for establishing Islamic biotechnology center in order to develop the agriculture and related sectors for the socio-economic prosperity of Muslim countries. Addressing the 3rd International Conference on Agriculture, Food Security and Biotechnology on an other day, he said that government believes that practical collaboration among the Muslim countries in the cutting edge areas of modern biotechnology was the need of time. The event was organized by Pakistan Agricultural Research Council (PARC) in collaboration with COMSATS, Islamic Educational, Scientific and Cultural Organization (ISESCO) and CIMMYT. The aim of the conference was to share the international best practices of using the biotechnology for the development of agriculture sector and food security. The minister termed the exchange of eminent scientist for short term and graduating students among Islamic countries as another good form of cooperation. He called upon the scientists for encouraging and promoting smart agricultural practices to build the resilience in agri-sector. Pakistan was working on the development of infrastructure for using modern and innovative technologies including the biotechnology for uplift of agriculture, health and industrial sectors of the country, he added. Pakistan has improved its crop yield and productivity over the years and it was producing surplus of wheat, maize, potato and sugarcane, he added. He said that scientist and biotechnologist in Pakistan has achieved the diversification in seed development and moved to a higher value added seeds, particularly in the crops sector. The minister said that all the modern techniques should be replicated after tailor-made alterations keeping in view of local settings and environmental factors.

See the article here:
Bosan for establishing Islamic Biotechnology Centre - Pakistan Observer

Read More...

Page 1,020«..1020..1,0191,0201,0211,022..1,0301,040..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick